EPRS and the EES it regulates may be a promising target for development of novel therapies, or the repurposing of existing therapies, to treat patients with ER+ breast cancers whose tumors do not respond to currently-used endocrine modulators. This evidence concerns the gene ESR1 and breast cancer.